P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In

News Categories

 

 

 

Once-Daily Edoxaban Reduces VTE Recurrence Compared With Warfarin in Phase III Study

Treatment also reduces clinically relevant bleeding (December 9)

Positive results have been reported from a subgroup analysis of 771 cancer patients enrolled in a phase III study evaluating the once-daily factor Xa inhibitor edoxaban (Daiichi Sankyo Company, Inc.) in patients with either a history of cancer (n = 563) or active cancer (n = 208). The findings were presented Dec. 9 at the 2013 American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans.

Treatment with once-daily edoxaban showed a numerically lower incidence of recurrent symptomatic venous thromboembolism (VTE) compared with warfarin (3.7% vs. 7.1%, respectively; hazard ratio [HR], 0.53). Edoxaban was also associated with a lower incidence of clinically relevant bleeding (major or non-major) compared with warfarin (12.4% vs. 18.8%, respectively; HR, 0.64).

These findings were consistent with the results from the total study population of 8,292 patients, in whom once-daily edoxaban met the primary efficacy endpoint of non-inferiority for the treatment and prevention of VTE and superiority for the pre-specified principal safety outcome of clinically relevant bleeding compared with warfarin.

In a subset of 208 patients with active cancer who received once-daily edoxaban, the VTE recurrence rate was 3.7% compared with 7.1% for warfarin (HR, 0.55), and the incidence of clinically relevant bleeding was 18.3% compared with 25.3% for warfarin (HR, 0.72).

Source: Daiichi Sankyo, Inc.; December 9, 2013.

More stories